Cellectis has raised $164m from a US public offering to expand its CAR-T and gene-editing capabilities. The French company is planning to invest $100m of the funding on expanding commercial production, including setting up a manufacturing plant for its CAR-T candidates, $20m on starting clinical development on another programme and $30m to develop its gene-editing technology for non-oncological uses. Genentech also plans to spend about $50m, mostly in Europe, on developing new treatments that target cancer cells with CRISPR technology. Online This virtual event will bring together industry experts to discuss the increasing pace of pharmaceutical innovation, the need to maintain data quality and integrity as new technologies are implemented and understand regulatory challenges to ensure compliance. Ts has been converted into a new company, Allogene, which has taken over US rights to lead CAR-T UCART19 for acute lymphoblastic leukaemia, and is backed by $300m of funding.
Cellectis has raised $164m from a US public offering to expand its CAR-T and gene-editing capabilities. The French company is planning to invest $100m of the funding on expanding commercial production, including setting up a manufacturing plant for its CAR-T candidates, $20m on starting clinical development on another programme and $30m to develop its gene-editing technology for non-oncological uses. Genentech also plans to spend about $50m, mostly in Europe, on developing new treatments that target cancer cells with CRISPR technology. Ts has been converted into a new company, Allogene, which has taken over US rights to lead CAR-T UCART19 for acute lymphoblastic leukaemia, and is backed by $300m of funding.